A. Lyakhovich, C. Gasche
Nov 5, 2009
Citations
2
Influential Citations
97
Citations
Quality indicators
Journal
Alimentary Pharmacology & Therapeutics
Abstract
Background Mesalazine (mesalamine) (5‐ASA) is considered an anti‐inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis. Besides its anti‐inflammatory properties, 5‐ASA has been studied for cancer inhibitory activities as it seems to reduce colorectal cancer incidence in patients using this drug for long periods of time. However, detailed molecular mechanisms of drug action are vague.